^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MAPK4 (Mitogen-Activated Protein Kinase 4)

    i
    Other names: MAPK4, Mitogen-Activated Protein Kinase 4, Extracellular Signal-Regulated Kinase 4, MAP Kinase Isoform P63, Erk3-Related, P63-MAPK, MAPK 4, ERK-4, PRKM4, ERK4, MAP Kinase 4, P63MAPK, MAPK4, Erk4
    4ms
    p-Cymene Targets Multiple Oncogenic Pathways in Hepatocellular Carcinoma: Insights From Network Pharmacology and In Vitro Studies. (PubMed, Food Sci Nutr)
    Additionally, BCL2 and VEGF were downregulated, suggesting inhibition of cell survival and angiogenesis. These findings highlight p-cymene's multi-targeted anticancer effects in HCC cells, supporting its further evaluation in in vivo models and potential combination therapies for improved therapeutic outcomes.
    Preclinical • Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • JAK2 (Janus kinase 2) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CASP3 (Caspase 3) • CDK9 (Cyclin Dependent Kinase 9) • MAPK4 (Mitogen-Activated Protein Kinase 4)
    5ms
    The Impact of Proinflammatory M1 Macrophages on the Proliferation and Expression of Cyclin E2, Mitogen-Activated Protein Kinases 4 and 7 in Hepatocytes Isolated from a Diethylnitrosamine-Induced Hepatocellular Carcinoma Rat Model. (PubMed, Molecules)
    (4) Our findings indicate that CE2 expression is upregulated in PH/DEN cells, with a notable decrease in the presence of M1 macrophages. In contrast, compared with control macrophages, M1 macrophages did not significantly affect Mapk4/7 expression.
    Preclinical • Journal • IO biomarker
    |
    CCNE2 (Cyclin E2) • MAPK4 (Mitogen-Activated Protein Kinase 4)
    6ms
    Polystyrene microspheres could inhibit the ferroptosis of prostate cancer cells via USP39/IGF2BP3/MAPK4 axis. (PubMed, J Transl Med)
    These findings illuminate the complex relationship between environmental pollutants such as PS and cancer progression, offering new avenues for research and potential therapeutic interventions in prostate cancer.
    Journal
    |
    MAPK4 (Mitogen-Activated Protein Kinase 4) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3)
    9ms
    Astragaloside IV ameliorates Parkinson's disease by inhibiting TLR4/NF-κB-dependent neuroinflammation. (PubMed, Int Immunopharmacol)
    Importantly, AS-IV pretreatment can't counteract these LPS-EB Ultrapure-triggered effects, demonstrating its dependence on the TLR4/NF-κB signaling pathway. In conclusion, our findings indicate that AS-IV modulates microglial polarization and attenuates neuroinflammation by inhibiting the TLR4/NF-κB pathway, thereby ameliorating motor dysfunction and neuronal loss in PD mice.
    Journal • IO biomarker
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • TLR4 (Toll Like Receptor 4) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4) • MAPK4 (Mitogen-Activated Protein Kinase 4) • MAP2K3 (Mitogen-Activated Protein Kinase Kinase 3) • MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4) • MAPK3 (Mitogen-Activated Protein Kinase 3) • MAPK8 (Mitogen-activated protein kinase 8)
    9ms
    Targeting mitogen-activated protein kinase 4 for liver regeneration through QSAR-based virtual screening and unbiased MD simulation. (PubMed, Int J Biol Macromol)
    MM/PBSA binding free energy calculations further supported their high affinity (-43.90 ± 0.11 kcal/mol and - 45.70 ± 0.14 kcal/mol, respectively). Collectively, these results suggest that FDA3675381442 and NPC100204 are promising MKK4 inhibitors with strong and stable interactions, warranting further investigation as therapeutic candidates for cancer and liver regeneration.
    Journal
    |
    MAPK4 (Mitogen-Activated Protein Kinase 4) • MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4)
    10ms
    Exploring the mechanisms of artemisinin and its derivatives in the treatment of atopic dermatitis based on network pharmacology and molecular docking: A review. (PubMed, Medicine (Baltimore))
    ARS and its derivatives have the potential to treat AD. Artemisinin, artesunate, dihydroartemisinin, artemether, artemisinin and artemisinone could potentially treat AD by targeting MAPK14 and MAPK10.
    Review • Journal
    |
    IL17A (Interleukin 17A) • MAPK4 (Mitogen-Activated Protein Kinase 4) • MAPK14 (Mitogen-Activated Protein Kinase 14) • MAPK10 (Mitogen-Activated Protein Kinase 10)
    10ms
    Human umbilical cord mesenchymal stem cell-derived exosomal miR-199a-3p inhibits the MAPK4/NF-κB signaling pathway to relieve osteoarthritis. (PubMed, World J Stem Cells)
    hUC-MSC-derived exosomal miR-199a-3p alleviates OA by inhibiting the mitogen-activated protein kinase 4/nuclear factor-kappaB signaling pathway. The present findings suggest that miR-199a-3p delivery by hUC-MSC-Exos may be a novel strategy for the treatment of OA.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • MIR199A1 (MicroRNA 199a-1) • IL1B (Interleukin 1, beta) • MAPK4 (Mitogen-Activated Protein Kinase 4) • MIR199A (MicroRNA 199a)
    10ms
    Development and validation of a 16-gene T-cell- related prognostic model in non-small cell lung cancer. (PubMed, Front Immunol)
    High-risk patients responded better to AZD5991-1720, an MCL1 inhibitor, while low-risk patients showed improved responses to IGF1R-3801-1738, an IGF1R inhibitor, suggesting that risk stratification may help optimize treatment selection based on tumor-specific vulnerabilities...However, prospective validation is needed to confirm its clinical applicability. Potential limitations such as sample size and generalizability should be considered.
    Journal
    |
    LDHA (Lactate dehydrogenase A) • CD69 (CD69 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • BAIAP2 (BAR/IMD Domain Containing Adaptor Protein 2) • LATS2 (Large Tumor Suppressor Kinase 2) • MAPK4 (Mitogen-Activated Protein Kinase 4) • AKAP12 (A-Kinase Anchoring Protein 12) • CKAP4 (Cytoskeleton Associated Protein 4) • HOXC10 (Homeobox C10) • DSG2 (Desmoglein 2)
    |
    AZD5991
    11ms
    p53 transcriptionally activates DCP1B to suppress tumor progression and enhance tumor sensitivity to PI3K blockade in non-small cell lung cancer. (PubMed, Cell Death Differ)
    Moreover, the p53 agonist combined with the PI3K inhibitor can suppress NSCLC proliferation synergistically in vitro and in vivo. Collectively, this study not only uncovers the function and mechanism of the p53-DCP1B-MAPK4 axis in suppressing NSCLC progression but also suggests a promising combination strategy for treating NSCLC.
    Journal
    |
    MAPK4 (Mitogen-Activated Protein Kinase 4)
    1year
    Establishment of liquid-liquid phase separation-related prognostic model in lung adenocarcinoma and systematic analysis of its clinical significance. (PubMed, Int J Biol Markers)
    This work proposed a prognostic tool based on the LLPS-related gene signature to offer prospective and effective biomarkers for lung adenocarcinoma prognosis.
    Journal
    |
    MAGEA4 (Melanoma antigen family A, 4) • CRTAC1 (Cartilage Acidic Protein 1) • MAPK4 (Mitogen-Activated Protein Kinase 4)
    over1year
    C6 and KLRG2 are pyroptosis subtype-related prognostic biomarkers and correlated with tumor-infiltrating lymphocytes in lung adenocarcinoma. (PubMed, Sci Rep)
    In this study, we constructed a predictive risk model and identified two pyroptosis subtype-related gene expression patterns to improve the prognosis of LUAD. Understanding the subtypes of LUAD is helpful for accurately characterizing the LUAD and developing personalized treatment.
    Journal • Tumor-infiltrating lymphocyte
    |
    MAPK4 (Mitogen-Activated Protein Kinase 4)
    over1year
    Anti-liver cancer therapeutic targets and safety of usenamine A in experimental liver cancer. (PubMed, J Pharm Pharmacol)
    Usenamine A is a safe anticancer agent against hepatocellular carcinoma. Regulation of 12 cancer-associated genes and the correlated pathway network are its therapeutic targets.
    Journal
    |
    TP53 (Tumor protein P53) • MAPK4 (Mitogen-Activated Protein Kinase 4) • PRKACA (Protein Kinase CAMP-Activated Catalytic Subunit Alpha) • PRKCB (Protein Kinase C Beta) • DUSP4 (Dual Specificity Phosphatase 4) • DUSP5 (Dual Specificity Phosphatase 5) • E2F3 (E2F transcription factor 3) • LGR4 (Leucine Rich Repeat Containing G Protein-Coupled Receptor 4)